OBJECTIVES: The effect of sinuses of Valsalva on aortic bioprosthesis durability has not been investigated so far. The aim of this study was to compare durability of the Carpentier-Edwards aortic bioprosthesis in patients undergoing aortic valve and ascending aorta replacement as a composite bioconduit (Group A, case group) versus patients undergoing separate replacement of the aortic valve and ascending aorta, with preservation of the aortic root (Group B, control group), between January 2000 and January 2014.
INTRODUCTION
Biological aortic valve prostheses have been recently preferred over mechanical prostheses not only for isolated aortic valve replacement (AVR), but also for aortic root replacement according to the modified Bentall technique (bio-Bentall), due to patient and surgeon preference; optimal durability of the available prostheses with the longest follow-up; development of new generation prostheses with improved haemodynamics; and the satisfactory results of redo aortic valve surgery [1] [2] [3] [4] [5] [6] . Commercially available or hand-sewn valved conduits have been used [7] [8] [9] [10] [11] [12] [13] [14] . Hand-sewn conduits are usually assembled intraoperatively by sewing a commercially available stented or stentless biological aortic valve prosthesis inside a Dacron vascular graft.
The durability of biological aortic valve prostheses is limited by the development of structural valvular deterioration (SVD), which is associated with patient-and prosthesis-related characteristics [6, [15] [16] [17] . In addition, in patients undergoing bio-Bentall procedures, the absence of sinuses of Valsalva, which play an important role in the proper opening and closing movements of the native aortic valve, may similarly influence aortic valve prosthesis function [18] [19] [20] [21] . Sinuses of Valsalva have been recently recreated in vascular Dacron grafts used for aortic root replacement [8, 10, 12] . However, the effect of the absence of the sinuses of Valsalva on prosthesis SVD has not been well investigated and is still debated. There are few case series comparing long-term durability of aortic valve prostheses among patients who underwent aortic root replacement with Dacron grafts with or without the sinuses of Valsalva [10] .
Therefore, we designed this retrospective observational study in order to evaluate the impact of absence of the sinuses of Valsalva on long-term durability of the Carpentier-Edwards pericardial aortic prosthesis (Edwards LifeSciences, Irvine, CA, USA).
METHODS

Patients
A retrospective observational study was performed in a single university centre, in order to evaluate the impact of the absence of the native aortic root, precisely of the sinuses of Valsalva, on durability of the Carpentier-Edwards pericardial aortic bioprosthesis. Patient selection was performed as it follows:
Firstly, our clinic database was searched for consecutive patients who underwent concomitant AVR and replacement of the ascending aorta according to the modified Bentall technique with a hand-sewn biological conduit including a Carpentier-Edwards pericardial bioprosthesis. These patients, who underwent operation between January 2000 and January 2014 and showed a complete follow-up, formed Group A (case group, Fig. 1 ).
Then, we created a control group (Group B) including contemporary consecutive patients who, between January 2000 and January 2014, underwent separate AVR with a Carpentier-Edwards bioprosthesis and supracoronary ascending aorta replacement, and showed a complete follow-up (Fig. 1) . Patients who underwent concomitant replacement of one of the sinuses of Valsalva (usually the non-coronary sinus) were excluded. Thus, all Group B patients showed a completely preserved native aortic root and sinuses of Valsalva.
We included in Groups A and B only patients with a CarpentierEdwards bioprosthesis for the following reasons: patients with a Carpentier-Edwards prosthesis had the longest follow-up at our institution; the prosthesis has shown the best long-term durability in comparison with other aortic bioprosthesis [4] [5] [6] ; and we aimed at keeping the patient population as more homogeneous as possible, without including other aortic prostheses which may show different durability and haemodynamics.
Moreover, Group A patients were not compared with patients who underwent aortic root replacement with a composite bioconduit including recreated sinuses of Valsalva, such as the Biovalsalva (Vascutek Terumo Corporation, Glasgow, UK) conduit, since, at our institution, the Biovalsalva conduit has been implanted only since 2006, and it includes the Elan (Vascutek Terumo Corporation, Glasgow, UK) porcine stentless aortic valve. It has been demonstrated that pericardial versus porcine and stented versus stentless aortic prostheses may have different haemodynamics and durability [22] .
In both groups, patients undergoing multiple valve procedures, such as mitral valve reconstruction or replacement, were excluded. Similarly, patients who were lost to or showed an uncompleted follow-up ( Fig. 1) were excluded, since the present study focused on prosthesis durability.
Patient records were retrospectively reviewed. Follow-up was carried out by contacting surviving patients at home or their physician by phone and ended on 1 April 2015. Overall, for patients who survived hospital discharge, mean follow-up was 72 ± 40 months (range, 1-175 months). For Group A and B patients, mean follow-up was 81 ± 43 months (range, 5-175 months) and 65 ± 36 months (range, 1-175 months), respectively (P < 0.01) and was 100% complete. The first and the last transthoracic echocardiograms were retrieved by reviewing patient records and contacting the referring cardiologist, whenever possible, respectively [3] .
Descriptions of morbidity and mortality were based on the guidelines for reporting morbidity and mortality after cardiac valve [23] . Evidence of SVD was based on echocardiographic reports and confirmed intraoperatively for those who underwent redo AVR for SVD.
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The institutional ethics committee waived the need for patient consenting to the study.
Surgery
Patients signed an informed consent to AVR and replacement of the ascending aorta. All patients younger were informed about the advantages or disadvantages of receiving a biological prosthesis [3] .
At our institution, the technique for hand-sewn bioconduit assembly and implant, and the technique for separate replacement of the aortic valve and of the ascending aorta, as well as the postoperative patient management, did not change during the study period. After median sternotomy or j-shape sternotomy for minimally invasive approach, cardiopulmonary bypass was instituted by cannulating the ascending aorta or the proximal aortic arch for arterial inflow and the right atrium for venous outflow [3] . After the infusion of antegrade cardioplegia and aortotomy, the native aortic valve and the dilated ascending aorta were excised, and the aortic annulus was decalcified. If the aortic root was dilated (more than 4 cm), a replacement of the aortic valve and ascending aorta according to the modified Bentall technique and using a hand-sewn bioconduit was performed. Otherwise, separate AVR and supracoronary replacement of the ascending aorta was performed. The impact of patient age in the decision-making between composite versus separate replacement of the aortic valve and ascending aorta was usually weighted against the presence of concomitant comorbidities or need for additional cardiac procedures, such as CABG. Aortic valve prosthesis size was measured using custom-made seizers. In those patients requiring proximal or total replacement of the aortic arch, antegrade cerebral perfusion was performed through direct cannulation of the innominate and the left common carotid arteries. In these cases, bladder temperature was cooled down to 24-25°C.
In Group A patients, the bioconduit was assembled soon after sizing of the aortic valve and ascending aorta prostheses. The Carpentier-Edwards bioprosthesis was placed into the Dacron vascular graft, leaving a free margin of the tube of about 3-5 mm, in order to facilitate potential future redo AVR. The bioprosthesis was then fixed to the Dacron tube using a 3/0 polypropylene suture (Fig. 2) . Commercially available Dacron grafts without recreated sinuses of Valsalva were used. The self-assembled conduit was implanted using multiple 2-0 U-shaped single stitches reinforced with pledgets passed through the aortic annulus and the 3-5 mm Dacron sleeve beneath the prosthesis [9, 14] . Consequently, the bioprosthesis sat in a supra-annular position, thus maximizing blood flow. Coronary ostia were implanted using the button technique using 6/0 polypropylene sutures. Distal anastomosis to the remaining ascending aorta or aortic arch was performed before or after aortic root replacement according to surgeon preference or operative strategy.
On the contrary, in Group B patients, aortic valve was first implanted in a supra-annular position using multiple 2-0 U-shaped single stitches reinforced with pledgets passed through the aortic annulus. Then, the Dacron graft was sewn to the aortic root at the sinotubular junction using a 3/0 or a 4/0 polypropylene suture. The Dacron grafts were sized in order to restore a normal diameter of the sinotubular junction.
Postoperatively, all patients were treated with unfractionated heparin until the removal of chest tubes and warfarin was initiated thereafter. After hospital discharge, patients with a biological prosthesis were anticoagulated with warfarin with a target international normalized ratio (INR) between 2 and 3 for 2 months. Thereafter, patients received only aspirin, if not otherwise indicated [3] . Patients usually underwent echocardiographic control before discharge from our institution or rehabilitation clinic, whenever possible. 
Data analysis
Data analysis was performed using SPSS 22.0 (IBM, NY, USA). Primary end-points were freedom from SVD and redo AVR for SVD. Secondary end-points were mortality, freedom from cardiac reoperation of any type and thromboembolic events. Categorical and continuous variables were summarized as percentages and means ± standard deviation (SD) or median with interquartile range (IQR), respectively [3] . The independent-samples parametric Student's t-test and the χ 2 -test or the Fisher's exact tests were used for group comparisons of continuous and categorical variables, respectively [3] .
Survival estimates along with freedom from structural valve deterioration (SVD), redo AVR for SVD, cardiac reoperation of any type, thromboembolic events were calculated by the product-limit method of Kaplan-Meier. Differences among groups were quantified using the log-rank test [3] .
To account for the differences in patient characteristics among groups and to mitigate the lack of randomization, propensity scores were developed based on eight covariates in a logistic regression model with implantation of a composite hand-sewn bioconduit as the dependent variable. The categorical variables, which showed a difference among groups ( preoperative aortic valve regurgitation or stenosis, endocarditis, acute and chronic aortic dissection, coronary artery disease, cardiac redo and bicuspid aortic valve) and thus might have influenced the choice of operative strategy (bioconduit versus separate AVR and replacement of the ascending aorta), were used as covariates.
Study end-points were thus evaluated using propensity scores as balancing scores in three ways: firstly, 94 Group A patients were matched to 94 Group B patients. Secondly, all included patients were stratified into quintiles on the basis of having similar propensity scores. Each end-point was then evaluated within each quintile. This evaluation should include as much information as possible, and matching exactness was considered of secondary importance. Finally, a Cox forward stepwise logistic regression analysis including all patients was performed to identify independent risk factors only for SVD. The model was constructed including risk factors with univariate P < 0.1 and the propensity score for composite bioconduit. The results were controlled by performing a backward logistic regression analysis and were reported as odds ratios (ORs) with 95% confidence interval (CI) and corresponding P-value.
Two-tailed P ≤ 0.05 were considered significant.
RESULTS
Patient groups
Among the 2373 patients who, between January 2000 and January 2014, underwent AVR with a Carpentier-Edwards bioprosthesis for any reason at our institution, 332 (14%) patients underwent AVR and replacement of ascending aorta, in 151 (45%) patients according to the modified Bentall technique with a hand-sewn bioconduit, and in 181 (56%) patients separately (Fig. 1) . Among the patients who underwent AVR and replacement of the ascending aorta with a bioconduit, 133 (88%) patients showed a complete follow-up and formed Group A. The 18 (12%) patients, who were excluded for lack of follow-up, did not show different preoperative mortality risk in comparison with Group A patients (EUROSCORE, 6 ± 7 vs 5 ± 5% in Group A patients, P = 0.21).
Among the patients who underwent separate AVR and supracoronary replacement of the ascending aorta, 162 (90%) patients showed a complete follow-up and formed Group B. Similarly to Group A, the 19 (10%) patients excluded for lack of follow-up did not show different preoperative mortality risk in comparison with Group B patients (EUROSCORE, 7 ± 6 vs 4 ± 4% in Group B patients, P = 0.13).
Patient characteristics
Groups A and B showed preoperative heterogeneity regarding some variables, such as cardiac redo and presence of coronary artery disease, aortic valve regurgitation or stenosis, bicuspid aortic valve, acute or chronic dissection and acute endocarditis, which were used to calculate the propensity scores (Table 1) . Other variables, which might potentially have been risk factors for SVD, such as diabetes mellitus, hyperlipidaemia, dialysis and hypertension, showed no difference among groups.
Intraoperatively (Table 2) , more Group A patients required complete arch replacement and consequently antegrade cerebral perfusion times were longer in Group A than in Group B. Expectedly, cardiopulmonary bypass and cross-clamp times were 
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longer in Group A than in Group B patients. The median size of implanted bioprosthesis was similar among groups, but more Group A patients received a 27-mm prosthesis. Postoperatively (Table 2 ), Group A and B patients showed similar hospital times and in-hospital mortality. However, Group A patients required more rethoracotomy for bleeding than Group B patients, which instead showed more episodes of atrial fibrillation. Trans-prosthetic gradients were similar among groups.
Structural valve deterioration and non-structural valve dysfunction
There was no difference among groups regarding freedom from SVD at 5 and 12 years, before and after matching through propensity score and after stratification into quintiles of propensity score (Tables 3 and 4, Fig. 3A) . At transthoracic echocardiography, 11 Group A versus 8 Group B patients showed SVD, which was due to prosthesis regurgitation (Group A, n = 5; Group B, n = 1), stenosis (Group A, n = 2; Group B, n = 5) or combined (Group A, n = 4; Group B, n = 2). At the univariate analysis, which considered most of the variables reported in Table 1 , only the presence of coronary artery disease (P = 0.09), increasing patient age (P < 0.01) and EUROSCORE (P = 0.01) were associated with SVD. At the forward logistic regression Cox multivariate analysis, which included the propensity scores, increasing patient age emerged as protective factor against SVD (OR: 0.95, 95% CI: 0.92-0.99, P = 0.01). The backward logistic regression Cox analysis confirmed the previous result. Among the 11 Group A patients with SVD, 10 (91%) patients were younger than 65 years. Similarly, among the 8 Group B patients with SVD, 6 (75%) patients were younger than 65 years.
Only 3 Group A patients showed non-structural valve dysfunction, due to endocarditis. The transthoracic echocardiography showed vegetations in all patients, but a perfectly functioning bioprosthesis. 
Redo aortic valve replacement for structural valve deterioration and cardiac redo of any type
There was no difference among groups regarding freedom from redo AVR due to SVD and freedom from cardiac redo of any type, before and after matching through propensity score and after stratification into quintiles of propensity score (Tables 3 and 4 , Fig. 3B ). However, in the unmatched patients, there was a trend towards better freedom from redo AVR for SVD in Group B patients after 12 years (Table 3 and Fig. 3B ). Overall, 12 Group A patients underwent a cardiac redo of any type. Among these patients, 6 (50%) patients underwent redo AVR for SVD. Five patients received a biological prosthesis (Carpentier-Edwards, n = 3; Perceval (Sorin Group, Milan, Italy), n = 1; Trifecta (St Jude Medical, Minneapolis, MN, USA), n = 1), and 1 patient a mechanical prosthesis. One patient died in hospital, 1 patient showed a prolonged hospital stay as a consequence of intraoperative acute type A dissection, whereas the remaining 3 patients showed an uncomplicated postoperative course. The remaining 6 patients underwent mitral valve surgery (n = 3), aortic arch replacement (n = 1), reconstruction of the tricuspid valve (n = 1) and redo AVR and replacement of the ascending aorta due to prosthesis endocarditis (n = 1). Instead, 5 Group B patients underwent a cardiac redo of any type. Among these patients, 3 patients underwent redo AVR for SVD. Two patients received again a Carpentier-Edwards prosthesis and 1 patient a mechanical prosthesis. All patients had an uncomplicated postoperative course. The remaining 2 patients underwent mitral valve replacement and mitral valve reconstruction associated with CABG. Significantly, no Group B patient underwent cardiac redo for dilatation of the preserved aortic root.
Intraoperative inspection confirmed the presence of a degenerated prosthesis in all patients who underwent AVR for SVD. On the contrary, in the remaining patients undergoing cardiac redo, preoperative transthoracic echocardiography showed a functioning aortic bioprosthesis.
Survival, cerebrovascular events and echocardiography
There was no difference among groups regarding survival at 5-and 12-year follow-up, before and after matching through propensity score, and after stratification into quintiles of propensity score (Tables 3 and 4, Fig. 4 ). Patients in quintile 5 showed different (Table 4) . Thirty-two (25%) Group A and 25 (16%) Group B patients died after hospital discharge. Among these patients, cardiac-related deaths were reported in 23 (18%) Group A versus 14 (9%) Group B patients (P = 0.03), malignancy-related deaths in 4 (3%) Group A versus 1 (1%) Group B patients (P = 0.18) and deaths due to other reasons in the remaining 5 (4%) Group A versus 10 (7%) Group B patients (P = 0.34). This difference in the prevalence of cardiac mortality among groups was not related to the different surgical approach for replacement of the aortic valve and ascending aorta, since death was related to the initial operation only in 3 Group A ( prosthesis endocarditis, n = 2; and redo for SVD, n = 1) patients and in none Group B patient (P = 0.23).
Similarly, there was no difference among groups regarding freedom from cerebrovascular events at 5-and 12-year follow-up, before and after matching through propensity score and after stratification into quintiles of propensity score (Tables 3 and 4) . Five (4%) Group A (stroke, n = 3; transitory ischaemic attack, n = 2) versus 7 Group B (stroke, n = 3; transitory ischaemic attack, n = 4) patients showed a cerebrovascular event (P = 0.99). Three Group A and 4 Group B patients recovered completely from the cerebral insult.
At last, transthoracic echocardiographic control was performed after a mean of 62 ± 38 months (range, 1-164 months); maximal trans-prosthetic gradients were significantly lower in Group A patients (P = 0.03). In addition, in Group B patients, no dilatation of the native aortic root and of the native sinuses of Valsalva was reported at long-term follow-up.
DISCUSSION
This study yielded the following main results. Firstly, the absence of sinuses of Valsalva did not influence the durability of the Carpentier-Edwards pericardial bioprosthesis within 12-year follow-up. At the multivariate analysis, only patient age remained an important factor influencing prosthesis durability. Secondly, at last transthoracic echocardiographic control, mean and maximal trans-prosthetic gradients were even lower in patients who underwent aortic root replacement with a bioconduit than in patients who underwent separate AVR and supracoronary replacement of the ascending aorta with preservation of the native sinuses of Valsalva. Finally, patients who underwent separate AVR and supracoronary replacement of the ascending aorta did not show any dilatation of the native aortic root requiring cardiac redo at longterm follow-up.
Although data were retrospectively recorded and analysed, the validity of these conclusions was supported by the following study characteristics. This study included one of the most numerous case series of patients who underwent aortic root replacement with a hand-sewn composite bioconduit carrying a Carpentier-Edwards aortic bioprosthesis [13] . Patients in both groups underwent AVR with the same prosthesis. For the first time, we evaluated the effect of the true native sinuses of Valsalva on long-term prosthesis durability. Thus, we did not evaluate the effect of sinuses, which were recreated in Dacron grafts and are only an imitation of the native sinuses [10, 20] . Finally, we took into account the lack of randomization using propensity score analysis and confirmed the previous results after matching through propensity score and stratification into quintiles of propensity score.
This study cast additional light on a topical theme in cardiac surgery, since, over the last decade, conduits carrying a biological aortic prosthesis, such as the Carpentier Edwards or the SJM SPV Toronto, have become an alternative to the traditional conduits with a mechanical aortic prosthesis for aortic root replacement according to the modified Bentall technique [7] [8] [9] [10] [11] [12] [13] [14] . Hand-sewn self-assembled or commercially available bioconduits have been preferred over the traditional homografts or pulmonary autografts, due to evidence of calcification and early degeneration in the former and aortic regurgitation in the latter [11] . Moreover, they are easily available in comparison with homografts and autografts. Satisfactory results have been also reported in patients younger than 65 years old [11] .
However, there is still concern about the long-term durability of the available bioconduits. Most of the implanted prostheses, such as the SJM SPV Toronto, showed limited durability beyond 10 years in isolated AVR [24] , and the available case series reporting on selfassembled bioconduits reached only a maximum of 10-year followup [9] . Dacron grafts with recreated sinuses of Valsalva have been developed and first used in patients who underwent aortic valve reimplantation or reconstruction [18, 20, 21] . In fact, the sinuses of Valsalva play an important role in the proper functioning of the native aortic valve and it can be hypothesized that the same favourable effects may improve the durability of aortic valve bioprostheses. In fact, Bottio et al. have recently demonstrated that the absence of the sinuses of Valsalva modified the diastolic and systolic behaviours of the tissue valve leaflets of a 21-mm Carpentier-Edwards and SJM-Biocor-Epic-Supra (St Jude Medical, Inc., St Paul, MN, USA) by reducing the time required for leaflet coaptation and increasing the valve closing volume and maximum transvalvular flow velocity. These effects might increase the working stress on the valve tissue, leading to possible premature SVD [19] . Similarly, Pisani et al. have recently shown that the presence of sinuses of Valsalva prevented an increase in the pressure decrease across the valve by the way of an increase of the effective orifice area [20] .
The following reasons may explain why the absence of sinuses of Valsalva did not have any impact on prosthesis durability. Firstly, in contrast to the in vitro results of Bottio et al. the intrinsic inertia of prosthetic glutaraldehyde-fixed leaflets and the presence of a rigid stent may make difficult for the vortices inside the sinuses to actually influence in vivo the dynamics of the leaflets during the cardiac cycle. Secondly, pressure gradients at follow-up were lower in patients without sinuses of Valsalva. In this case, the lower pressure gradients may be explained partially by the higher number of 27-mm prostheses in Group A than in Group B patients. Third, other patient-and prosthesis-related factors, such as young age or the presence of a prosthesis antimineralization treatment [6, 15, 17] , seem to be more important than the sinuses of Valsalva for SVD development. Indeed, several aortic valve prostheses, such as the Cryolife O'Brien (Cryolife, Inc., Kennesaw, GA, USA), the SPV Toronto and the Sorin Mitroflow (Sorin Group, Milan, Italy), which showed unsatisfactory durability at long-term follow-up, did not undergo any antimineralization treatment [15, 24, 25] . Finally, the negative haemodynamic impact of absence of sinuses of Valsalva may require longer follow-up time to appear. Therefore, studies with longer follow-up are warranted to clarify this aspect.
Although biological prostheses in hand-sewn bioconduits may develop SVD and thus require redo AVR, we used some tricks to delay SVD and to facilitate future potential redo AVR. Firstly, we used the Carpentier-Edwards bioprosthesis, which has recently shown very satisfactory durability results after 20 years of followup [6] . Second, we also left a 5-mm Dacron sleeve beneath the prosthesis suture line, as previously described by Urbanski et al. [9] , which allows easier redo AVR without removing the Dacron graft. This represents a great advantage over homografts and xenografts, which usually calcify as the manifestation of SVD, thus rendering redo AVR a surgical challenge [9, 14] . Anyway, postoperative results of redo AVR have been encouraging and improving during the last years. In-hospital mortality rates between 3 and 6% have been recently reported [3, 15] . It has also been speculated that transcatheter valve-in-valve techniques may further reduce mortality and morbidity after redo AVR in the future [3] .
Study limitations
The retrospective nature of this analysis introduced inherent limitations, although the lack of randomization was partly compensated by the propensity score analysis. In fact, over the study period, there could have been some selection criteria, which could have favoured complete aortic root replacement instead of separate AVR and supracoronary replacement of the ascending aorta, such as surgeon preference and patient life expectancy. Since these criteria could not be retrospectively quantified and categorized by continuous and categorical variables, they could not be used for the propensity score analysis. Randomization surely is more helpful in considering these potential confounding factors [3] .
The follow-up length was significantly different among groups. Moreover, the follow-up may have been too short and the number of patients with the longest follow-up available too few to validate our hypothesis. However, we did not aim at demonstrating the good durability of the Carpentier-Edwards aortic prosthesis, which other studies with a follow-up longer than 15 years have already shown [4] [5] [6] . Instead, we aimed at testing the hypothesis if the absence of sinuses could impair the good durability of the Carpentier-Edwards prosthesis or not. This hypothesis may be also tested at 12-year follow-up.
While all patients who survived until the end of follow-up had undergone at least one transthoracic echocardiographic control, aortic valve area (AVA), trans-prosthetic gradients and diameters of the preserved aortic root in Group B patients were not reported for all patients by the referring cardiologist. For this reason, AVA was not reported in the result section of this study and the presence of a dilated aortic root at follow-up was only qualitatively evaluated and reported.
CONCLUSIONS
This study was unable to demonstrate any effect of the sinuses of Valsalva on durability of the Carpentier Edwards aortic valve prosthesis. Other factors such as patient age and antimineralization treatment have greater impact on prosthesis durability. Any potential effect of the sinuses of Valsalva on prosthesis durability may emerge with longer follow-up.
